A Randomized, Open-label, 2-Way Crossover, Parallel-group Study in Healthy Male and Female Subjects to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2017
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 15 Feb 2017 Status changed from recruiting to completed.
- 17 Oct 2016 New trial record
- 14 Oct 2016 Status changed from not yet recruiting to recruiting.